Adeno Viral Vectors are powerful tools in the realm of gene therapy and vaccine development. These vectors are derived from adenoviruses, which are common viruses that typically cause mild respiratory infections in humans. Adenoviral vectors are engineered to deliver genetic material into target cells, facilitating gene transfer and expression of therapeutic or vaccine antigens. One of the key advantages of adenoviral vectors is their ability to efficiently infect a wide range of cells, both dividing and non-dividing, making them versatile vehicles for gene delivery. Additionally, adenoviral vectors can induce strong immune responses, enhancing their effectiveness in vaccine applications.
In vaccine development, adenoviral vectors are utilized to deliver genes encoding antigens from pathogens such as viruses or bacteria. These antigens stimulate the immune system to mount a robust response, priming the body to recognize and combat the actual pathogen upon exposure. Adenoviral vector vaccines have shown promise in protecting against diseases like Ebola, HIV, and COVID-19. Moreover, adenoviral vectors have been employed in gene therapy to treat genetic disorders, cancer, and other diseases. By delivering therapeutic genes to target cells, adenoviral vectors can correct genetic defects, modulate cellular functions, or induce tumor cell death. In conclusion, adenoviral vectors represent a versatile and potent tool for gene therapy and vaccine development, holding promise for addressing a wide range of medical challenges and improving human health. Continued advancements in vector engineering and clinical research will further harness the potential of adenoviral vectors to benefit patients worldwide.
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey